BTIG on Aldeyra Therapeutics (ALDX): CRL 'hard to defend,' path to clarity within 90 days
Tweet Send to a Friend
BTIG analyst Thomas Shrader reiterated a Buy rating and $9.00 price target on Aldeyra Therapeutics (NASDAQ: ALDX)The analyst commented, "Another ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
